After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

WASHINGTON, DC - NOVEMBER 18: U.S. President Donald Trump (R) meets with Crown Prince and Prime Minister Mohammed bin Salman of Saudi Arabia during a bilateral meeting in the Oval Office of the White ...

Your support goes further this holiday season. When you buy an annual membership or give a one-time contribution, we’ll give a membership to someone who can’t afford access. It’s a simple way for you ...

The Architects of AI drove the economy, shaped geopolitics, and changed the way we interact with the world. by Charlie Campbell, Andrew R. Chow and Billy Perrigo by Sam Jacobs by D.W. Pine ...

Current political and economic issues succinctly explained. Section 232 tariffs aim to protect U.S. national security. Created by the Trade Expansion Act of 1962, Section 232 empowers the president to ...

Katsuji Nakazawa is a Tokyo-based senior staff and editorial writer at Nikkei. He spent seven years in China as a correspondent and later as China bureau chief and was the 2014 recipient of the Vaughn ...